Details of the Drug

General Information of Drug (ID: DMHXMYU)

Drug Name

LY3361237

Indication

Disease Entry	ICD 11	Status	REF
Sjogren syndrome	4A43.20	Phase 2	[1]
Systemic lupus erythematosus	4A40.0	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B- and T-lymphocyte attenuator (BTLA)	TTER58P	BTLA_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05781451) A Phase 2, Open Label Study of Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT05123586) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus. U.S.National Institutes of Health.